Drug reference
brentuximab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Oncology (Monoclonal antibody(Oncology))
Mechanism of action
CD30-directed antibody-drug conjugate (ADC) consisting of chimeric IgG1 antibody cAC10, specific for human CD30 and the microtubule disrupting agent, monomethyl auristatin E (MMAE, or vedotin). Conjugate binds to cell expressing the CD30 antigen and forms a complex that is internalized within the cell and MMAE is released.
Common side effects
- Constipation
- Neutropenia
- Anemia
- Vomiting
- Pyrexia
- Peripheral sensory neuropathy
- Diarrhea
Related conditions
Frequently asked questions
What drug class is brentuximab?
brentuximab belongs to: Oncology.
How does brentuximab work?
CD30-directed antibody-drug conjugate (ADC) consisting of chimeric IgG1 antibody cAC10, specific for human CD30 and the microtubule disrupting agent, monomethyl auristatin E (MMAE, or vedotin). Conjugate binds to cell expressing the CD30 antigen and forms a complex that is internalized within the cell and MMAE is released.
What are the common side effects of brentuximab?
Constipation, Neutropenia, Anemia, Vomiting, Pyrexia, Peripheral sensory neuropathy, Diarrhea
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.